Jorris Jan Wilms Biography and Net Worth

Sr. VP & COO of Y-mAbs Therapeutics

Joris Wiel Jan Wilms is the Sr. VP & COO at Y-Mabs Therapeutics Inc.

How do I contact Jorris Wiel Jan Wilms?: The corporate mailing address for Mr. Jan Wilms and other Y-mAbs Therapeutics executives is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. Y-mAbs Therapeutics can also be reached via phone at (646) 885-8505 and via email at [email protected]. Learn More on Jorris Wiel Jan Wilms' contact information.
Has Jorris Wiel Jan Wilms been buying or selling shares of Y-mAbs Therapeutics?: Jorris Wiel Jan Wilms has not been actively trading shares of Y-mAbs Therapeutics in the last ninety days. Learn More on Jorris Wiel Jan Wilms' trading history.
Who are Y-mAbs Therapeutics' active insiders?: Y-mAbs Therapeutics' insider roster includes Thomas Gad (Insider), Jorris Jan Wilms (Sr. VP & COO ), Bo Kruse (CFO), Vignesh Rajah (CMO), and Johan Wedell-Wedellsborg (Director). Learn More on Y-mAbs Therapeutics' active insiders.
Are insiders buying or selling shares of Y-mAbs Therapeutics?: During the last twelve months, Y-mAbs Therapeutics insiders bought shares 4 times. They purchased a total of 223,399 shares worth more than $1,413,938.86. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 301,155 shares worth more than $3,229,807.80. The most recent insider tranaction occured on September, 16th when insider Thomas Gad sold 30,000 shares worth more than $389,100.00. Insiders at Y-mAbs Therapeutics own 22.5% of the company. Learn More about insider trades at Y-mAbs Therapeutics.
Information on this page was last updated on 9/16/2024.

Jorris Wiel Jan Wilms Insider Trading History at Y-mAbs Therapeutics

Jorris Wiel Jan Wilms Buying and Selling Activity at Y-mAbs Therapeutics

Y-mAbs Therapeutics Company Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Today's Range

Now: $10.23

$9.85

$10.56

50 Day Range

MA: $13.82

$10.54

$15.69

2 Week Range

Now: $10.23

$5.29

$20.90

Volume

87,767 shs

Average Volume

329,622 shs

Market Capitalization

$458.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad